menu
    • menu
    [{"orgOrder":0,"company":"Cambium Bio","sponsor":"Aventacell Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"CAM-101","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cambium Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cambium Bio \/ Aventacell Biomedical","highestDevelopmentStatusID":"8","companyTruncated":"Cambium Bio \/ Aventacell Biomedical"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"},{"orgOrder":0,"company":"PolyActiva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"AUSTRALIA","productType":"HPAPI","year":"2022","type":"Inapplicable","leadProduct":"Latanoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"PolyActiva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant, Sustained Release","sponsorNew":"PolyActiva \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PolyActiva \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cambium Bio

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Cambium Bio

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Aventacell Biomedical

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cambium Bio Successfully Closes A$3.0M Financing Round

                            Details : The proceeds will primarily support the advancement of CAM-101 Elate Ocular through its registration-enabling Phase 3 clinical trials for dry eye disease.

                            Product Name : CAM-101

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : CAM-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Aventacell Biomedical

                            Deal Size : $3.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PolyActiva

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            PolyActiva

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolyActiva Announces Positive Phase IIa Results for PA5108 Ocular Implant

                            Details : PA5108 Ocular Implant with Prezia™ technology are being developed to offer a safe and effective, fully biodegradable therapy, which is investigated for the treatment of Open-Angle Glaucoma .

                            Product Name : PA5108

                            Product Type : HPAPI

                            Upfront Cash : Inapplicable

                            February 17, 2022

                            Lead Product(s) : Latanoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Opthea

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Opthea

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sozinibercept,Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Opthea Files for a $150 Million US IPO

                            Details : Opthea is working on a new drug that targets other VEGF proteins from those approved, including Bayer/Regeneron’s Eylea as well as Lucentis, namely VEGF-C and VEGF-D, for use in combination with VEGF-A drugs.

                            Product Name : OPT-302

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            September 25, 2020

                            Lead Product(s) : Sozinibercept,Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $150.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Opthea

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed

                            Opthea

                            Australia arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sozinibercept,Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Opthea Completes Successful Meetings with FDA and EMA for OPT-302 Phase 3 Clinical Program in Wet AMD

                            Details : The outcome of the meetings supports the progression of OPT-302 into Phase 3 and pre-commercial development. The company is on-track to initiate Phase 3 trials in early 2021.

                            Product Name : OPT-302

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 21, 2020

                            Lead Product(s) : Sozinibercept,Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth